Careers


Current Open Positions

Position:  Sr. Manager/Associate Director, Regulatory Affairs

Fremont, CA

The Sr. Manager/ Associate Director of Regulatory Affairs is responsible for the development and implementation of sound regulatory strategies and direction for assigned Quark Project Teams under the leadership of the Senior Director of Regulatory Affairs and Quality Assurance. S/he must have a comprehensive understanding of FDA/EU/ICH requirements, principles, concepts, industry practices, and standards. In this hands-on role, s/he coordinates, reviews and edits the preparation of regulatory documents. Duties include preparing, reviewing, and editing of clinical trial applications (CTAs), investigational new drug applications (INDs), and key documents associated with these applications as appropriate and in compliance with national and international regulations and laws (e.g. Annual updates, Investigator’s Brochure, labeling). The position provides the opportunity to provide input into a wide variety of drug development aspects associated with Regulatory Affairs.

ESSENTIAL DUTIES AND RESPONSIBILITIES include the following. Other duties may be assigned.

  • Represents Regulatory Affairs in project teams to develop product registration strategies and development plans aimed at achieving product application approvals.
  • Provide expert guidance to project teams on regulatory mechanisms to optimize product development.
  • Analyze changing regulatory requirements, evaluate risk, and establish contingency plans to assure timely submissions.
  • Develop and maintain effective working relationships with multiple international regulatory agencies, as well as represent Quark at meetings with various regulatory agencies.
  • Ensure that documents and regulatory submissions for domestic and international product development and registration are complete, organized, and compliant with applicable regulations.
  • Provide regulatory guidance to functional areas to ensure understanding and compliance with appropriate regulations and guidelines.
  • Regularly interact with senior management.


    Minimum Requirements

  • Bachelor’s Degree in physical/life sciences.
  • Seven or more years of Regulatory Affairs experience in the pharmaceutical or biotech industries required.
  • Knowledge of drug development, product licensure, and regulatory submissions.
  • Knowledgeable in ICH/cGMP/GLP/GCP, and regulatory guidelines as applied to the entire Development lifecycle of biotech and pharmaceutical companies.
  • Successful experience in the preparation of INDs and CTAs.
  • Knowledge of eCTD submission structure and process a plus.
  • Demonstrated successful FDA interactions.
  • Experience with US and international regulatory practices and procedures.
  • Flexibility and willingness to multitask and change priorities in a dynamic environment.
  • Strong organizational, planning, problem solving, and decision-making skills.
  • Excellent written and verbal communication skills and collaborative working style.
  • Desirable to have experience in renal, hepatic, transplant and/or ocular indications.




Position:


Contractor:  Sr. Clinical Data Analyst

Reports to:  Director, Clinical Data Management

Location:  Boulder, CO

Quark Pharmaceuticals is seeking an experienced professional to oversee and manage CRO data management activities for Quark sponsored studies.

       
         Primary Responsibilities:

  • Provide data management expertise and support project teams for assigned projects
  • Coordinate, review and approve Electronic Data Capture (EDC) systems creation, testing, release and maintenance.
  • Review, approval and monitoring of data management documents and activities
  • Oversee data reconciliation, database lock and final reporting.
  • Coordinate sponsor team level data management issues.
  •  Primary CDM liaison with CROs.
  • Assist other Data Management staff with  operational tasks on other studies as appropriate.
  • Perform other tasks as assigned by Director.



        Requirements

  • Bachelors or Masters degree in Sciences (Biology, Computer/Statistics, etc.) Life Sciences preferred.
  • Minimum 5 years of relevant data management experiences in biotech or pharmaceutical industry.
  • CRO management experience or data management experience at a CRO.
  • Experience with Electronic Data Capture – Medidata Rave experience preferred.
  • Excellent communication skills (verbal and written).
  • Ability to work independently and in team environment.
  • Knowledge of FDA regulatory requirements/GCP guidance.
  • Strong attention to detail.


 

How to Apply

To apply for a current open position please send your resume or curriculum vitae to Quark Pharmaceuticals as follows: 

For US positions:
Quark Pharmaceuticals, Inc .
Attn: Human Resources
Email: HR_USA@quarkpharma.com

For Israel positions:
QBI Enterprises, Ltd.
Attn: Human Resources
Weizmann Science Park, P.O.B. 4071
Ness Ziona, 70400, Israel
Email: ISRAEL

Notice to Recruitment Agencies/Search Firms:

Please be aware that external placement fees are only available to Search Firms that have an executed Search Agreement with Quark Pharmaceuticals and that a specific search must be expressly authorized by Quark Pharmaceuticals. All unsolicited resumes/CV’s submitted through our Web site or to personal e-mail accounts of employees of Quark Pharmaceuticals shall be deemed property of Quark Pharmaceuticals. Quark Pharmaceuticals explicitly reserves the right to pursue and hire those candidates without any financial obligation to the recruiter or search firm. If you wish to develop a business relationship with Quark, you may do so only by providing your name, email address, phone number, agency name, and area(s) of specialty to the hyperlink to the appropriate HR group listed above. Quark does not accept phone solicitations. Quark will contact your company if there is a business need for your services.



 
1/4/2012
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007
 
5/3/2011
Rutgers Offers Hope in New Treatment for Spinal Cord Injuries
 
3/18/2011
In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months
 
10/20/2010
Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
 
8/18/2010
Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
 
7/15/2010
Nitto Denko and Quark Pharmaceuticals to Enter into Collaboration to Develop a Novel siRNA Anti-fibrotic Drug
 
6/28/2010
Quark Pharmaceutical’s QPI-1007 Exhibits Neuroprotective Effects in Glaucoma Model
 
6/24/2010
Quark Pharmaceuticals Announces Presentations of its Two siRNA Drug Candidates at Glaucoma & Retinopathies 2010
 
6/15/2010
Quark Granted European Orphan Drug Status for QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients
 
6/10/2010
Quark Pharmaceuticals Closes $10 Million Financing
SBI Holdings, Inc. CEO Yoshitaka Kitao Appointed to Board. Funds to Support Advancing Clinical Pipeline.
 
5/17/2010
Quark Pharmaceuticals Announces Nature Medicine Publication for Role of RTP801 in Pulmonary Injury and Emphysema
 
5/6/2010
Quark Pharmaceuticals Development Partner Pfizer Presents In Vivo Activity of PF-04523655 at ARVO
 
5/4/2010
Quark to Present Data on Predicting Risk of Delayed Graft Function in Kidney Transplant Patients at American Transplant Congress
 
5/4/2010
Quark to Present Phase I Data for QPI-1002 in DGF
 
3/1/2010
Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
 
2/16/2010
FDA Grants Orphan Drug Status for Quark’s QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients
 
12/6/2009
Quark Pharmaceuticals Poised to Advance Clinical Studies of QPI-1002
First Synthetic siRNA Administered Systemically to Humans for the Prophylaxis of Acute Kidney Injury and Delayed Graft Function
 
11/19/2009
Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
 
11/2/2009
Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
 
10/26/2009
Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
 
8/4/2009
Quark Pharmaceuticals to Participate in IBC’s Oligonucleotide Therapeutics: From Concept to Implementation Conference
 
7/28/2009
Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
 
6/9/2009
Quark Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
 
5/14/2009
Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
 
5/11/2009
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
 
4/20/2009
Quark Pharmaceuticals Presents at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
 
3/9/2009
Quark Pharmaceuticals Presents at Asia TIDES Conference
Highlights First Systemic siRNA Administered in Humans and Quark’s Proprietary siRNA Structures
 
1/8/2009
Quark Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Kidney transplantation to be Quark’s second indication with clinical-stage, systemically administered siRNA product candidate for Delayed Graft Function
 
12/1/2008
Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
Presentation to Highlight Results of Ocular Neuroprotection Candidate
 
10/13/2008
Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Quark siRNAs Examined Alone and in Combination with Chemotherapy
 
9/25/2008
Quark Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Data Validates Neuroprotective Effect of Quark’s New RNAi product on dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma
 
9/17/2008
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
 
7/30/2008
Quark Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in DME
Clinical Program Leverages Quark’s RNAi Technology
 
4/7/2008
Quark Receives FDA Approval of IND For Kidney Transplant
Quark’s second siRNA drug delivered systemically
 
4/7/2008
Quark Closes $27 Million Financing
Funds Will Support Clinical Development of Pipeline Products
 
12/23/2007
Quark to Present at JPMorgan 26th Annual Healthcare Conference
Quark Pharmaceuticals to Present New Preclinical Proof of Concept Results at JPMorgan 26th Annual Healthcare Conference
 
11/19/2007
Quark Announces First Systemic siRNA Dosing
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans. Commences Phase I Clinical Trial of Proprietary siRNA Molecule in Acute Renal Failure.
 
10/23/2007
Quark to Present at CIBC and Acumen BioFin Rodman & Renshaw
Quark Pharmaceuticals to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
 
10/10/2007
Development Milestone Payment from Mitsubishi
Quark Pharmaceuticals, Inc. to Receive Development Milestone Payment from Mitsubishi Pharma Corporation
 
9/25/2007
Development of Proprietary siRNA Compounds for Noise-Induced Hearing Loss
Quark Pharmaceuticals Signs Collaboration Agreement with University of Michigan for Development of Proprietary siRNA Compounds for Noise-Induced Hearing Loss
 
8/28/2007
Patent Application on RNAi molecules
 Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications To Its RNAi Molecules
 
8/21/2007
Agreement with University of NY
Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
 
8/6/2007
Positive Preclinical Results
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Quark to initiate Phase 1 trial of AKIi-5 as the first human clinical study involving the systemic delivery of siRNA
 
7/31/2007
Silence Therapeutics and Quark
Silence Therapeutics plc and Quark Pharmaceuticals, Inc. (“Quark”), announced today an expansion of their current strategic technology licensing agreement
 
9/26/2006
Pfizer and Quark
Pfizer expands research commitment to ophthalmology through licensing agreement with quark biotech...
 
6/19/2005
COPD
Quark Biotech Discovers Role of RTP801 as Signaling Molecule in Cigarette Smoking-Induced Pulmonary Injury...
Web Development HomeProductsContact ©2007 Quark Pharmaceuticals, Inc.